In EC-Bmpr2-/- mice after 4 weeks of reoxygenation, AAV-Foxf1 reversed persistent pulmonary hypertension judged by normalization of right ventricular systolic pressure and right ventricular hypertrophy (Fig. 7d), pulmonary artery acceleration time/ejection time (PAAT/ET) (Supplementary Fig. 7c), the number of arteries per 100 alveoli at alveolar wall and duct level, and the percentage of muscularized arteries at these levels when compared with AAV-luciferase transfected control mice (Fig. 7d). This evidence concerns the gene FOXF1 and Right ventricular hypertrophy.